This report was recently updated on April 20 2024 with the latest and most recent
market numbers
Global Companion Diagnostics Market Size, Trends & Analysis - Forecasts to 2029 By Technology Type (Polymerase Chain Reaction, Immunohistochemistry, In-situ Hybridization, Next Generation Gene Sequencing, and Others), By End User (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs, and Others), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global companion diagnostics market is estimated to exhibit a CAGR of 4.4% from 2024 to 2029. Companion diagnostics are tests designed to identify specific biomarkers in patients, aiding in selecting appropriate therapies, particularly in personalized medicine. By analyzing genetic or protein markers, these tests help predict how patients will respond to specific treatments.
Several factors drive the growth of the global companion diagnostics market. The growing understanding of genetic variations' impact on disease susceptibility and treatment response has led to a surge in demand for companion diagnostics, which aid in identifying effective treatments for individual patients. The development of targeted therapies targeting specific disease molecular pathways has increased the need for companion diagnostics, which help identify patients most likely to benefit from these treatments, enhancing their efficacy and reducing adverse effects in non-responsive patients. Patients are increasingly recognizing the advantages of personalized medicine and the importance of companion diagnostics in guiding treatment decisions, leading to heightened pressure on healthcare providers and payers to integrate these diagnostics into clinical practice. The use of companion diagnostics is expanding beyond oncology to include infectious diseases, cardiovascular conditions, and neurological disorders, thereby driving market growth and diversification in this growing field.
Despite the various growth factors, several restraints hinder the growth of the global companion diagnostics market. Companion diagnostics often require significant research, development, and manufacturing investment, which can result in high costs for both companies and end users. This can limit adoption, particularly in resource-constrained healthcare settings.
On the basis of technology type, the market is segmented into polymerase chain reaction, immunohistochemistry, in-situ hybridization, next generation gene sequencing, and others. The polymerase chain reaction (PCR) segment is expected to be the largest segment during the forecast period. PCR's ability to detect specific genetic mutations with high sensitivity and specificity makes it indispensable in personalized medicine, particularly in oncology and infectious diseases. Its established presence, ease of integration into clinical workflows, and relatively low cost compared to newer technologies like NGS further contribute to its leading position in the companion diagnostics landscape.
The next generation gene sequencing (NGS) segment is expected to be the fastest-growing segment in the global companion diagnostics market during the forecast period. This technology enables simultaneous analysis of multiple genes, which is crucial for understanding complex genetic diseases, particularly cancers. NGS's growth is driven by technological advances, which have reduced costs and increased the speed and accuracy of genomic sequencing. Its increasing application in oncology, infectious diseases, and genetic disorders further expands its market potential. Regulatory bodies like the FDA have also supported NGS-based companion diagnostics, reinforcing its credibility and integration into healthcare systems.
On the basis of end user, the market is segmented into pharmaceutical & biopharmaceutical companies, reference laboratories, CROs and others. The pharmaceutical & biopharmaceutical companies segment is expected to hold the largest share of the market during the forecast period. This dominance is primarily due to their significant investment in the development of precision medicine and targeted therapies, which require companion diagnostics to identify the right patient populations. These companies invest in companion diagnostics to ensure that their drugs are effective for specific patient groups, making these tests integral to the commercial success of many new therapies.
The contract research organizations (CROs) segment is anticipated to be the fastest-growing in the global companion diagnostics market during the forecast period. The growth in this segment is driven by the increasing outsourcing of R&D activities by pharmaceutical and biopharmaceutical companies, including clinical trials, which now often incorporate companion diagnostic testing. CROs offer expertise and infrastructure that can accelerate the development and validation of companion diagnostics alongside therapeutic products. This trend toward outsourcing, combined with the overall growth of the personalized medicine field, positions CROs as a rapidly expanding market segment.
North America is expected to be the largest region in the global companion diagnostics market. The region has a highly developed healthcare system with access to advanced medical technologies and facilities. This infrastructure supports adopting and implementing companion diagnostics across various healthcare settings. North America is home to many leading pharmaceutical and biotechnology companies engaged in developing targeted therapies that require companion diagnostics. This concentration of companies drives significant investment in research and development in the region.
Asia Pacific is anticipated to be the fastest-growing region in global companion diagnostics during the forecast period. APAC countries are witnessing substantial growth in healthcare spending due to economic growth, wealth, and infrastructure investment, thereby promoting the adoption of advanced diagnostic technologies. APAC's aging population and high prevalence of chronic diseases like cancer and cardiovascular necessitate advanced diagnostic methods for effective treatment due to the significant demand for such diagnostics. The APAC region is experiencing a surge in personalized medicine acceptance, driven by the need for companion diagnostics to identify patients for the right treatments. APAC governments are promoting innovative healthcare solutions like companion diagnostics through regulatory support, research funding, and investments in biotech and pharmaceutical sectors.
Abbott, F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., Illumina Inc., Guardant Health, Thermo Fisher Scientific Inc., Biomerieux, Qiagen, and Myriad Genetics Inc., among others, are some of the key players operating in the global companion diagnostics market.
Please note: This is not an exhaustive list of companies profiled in the report.
In March 2024, Bayer and Thermo Fisher announced a collaboration to develop next-generation sequencing-based companion diagnostic assays (CDx) to identify patients eligible for Bayer's precision cancer therapies. The CE-marked in-vitro diagnostic can deliver results within 24 hours, offering decentralised genomic testing and rapid turnaround time.
In February 2024, Roche partnered with PathAI, a leading AI-powered technology company, to develop AI-enabled digital pathology algorithms for companion diagnostics. The agreement allows PathAI to work exclusively with Roche Tissue Diagnostics while RTD retains the ability to develop its own algorithms.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
2.4 Data Metrics on Feed Stocks
3 GLOBAL MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY TYPE
4.1 Introduction
4.2 Companion Diagnostics Market: Technology Type Scope Key Takeaways
4.3 Revenue Growth Analysis, 2023 & 2029
4.4 Polymerase Chain Reaction
4.4.1 Polymerase Chain Reaction Market Estimates and Forecast, 2021-2029 (USD Million)
4.5 Next Generation Gene Sequencing
4.5.1 Next Generation Gene Sequencing Market Estimates and Forecast, 2021-2029 (USD Million)
4.6 Immunohistochemistry
4.6.1 Immunohistochemistry Market Estimates and Forecast, 2021-2029 (USD Million)
4.7 In-situ Hybridization
4.7.1 In-situ Hybridization Market Estimates and Forecast, 2021-2029 (USD Million)
4.8 Others
4.8.1 Others Market Estimates and Forecast, 2021-2029 (USD Million)
5 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER
5.1 Introduction
5.2 Companion Diagnostics Market: End User Scope Key Takeaways
5.3 Revenue Growth Analysis, 2023 & 2029
5.4 Pharmaceutical & Biopharmaceutical Companies
5.4.1 Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecast, 2021-2029 (USD Million)
5.5 Reference Laboratories
5.5.1 Reference Laboratories Market Estimates and Forecast, 2021-2029 (USD Million)
5.6 CROs
5.6.1 CROs Market Estimates and Forecast, 2021-2029 (USD Million)
5.7 Others
5.7.1 Others Market Estimates and Forecast, 2021-2029 (USD Million)
6 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION
6.1 Introduction
6.2 North America Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.1 By Technology Type
6.2.2 By End User
6.2.3 By Country
6.2.3.1 U.S. Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.1.1 By Technology Type
6.2.3.1.2 By End User
6.2.3.2 Canada Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.2.1 By Technology Type
6.2.3.2.2 By End User
6.2.3.3 Mexico Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.3.1 By Technology Type
6.2.3.3.2 By End User
6.3 Europe Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.1 By Technology Type
6.3.2 By End User
6.3.3 By Country
6.3.3.1 Germany Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.1.1 By Technology Type
6.3.3.1.2 By End User
6.3.3.2 U.K. Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.2.1 By Technology Type
6.3.3.2.2 By End User
6.3.3.3 France Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.3.1 By Technology Type
6.3.3.3.2 By End User
6.3.3.4 Italy Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.4.1 By Technology Type
6.3.3.4.2 By End User
6.3.3.5 Spain Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.5.1 By Technology Type
6.3.3.5.2 By End User
6.3.3.6 Netherlands Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Technology Type
6.3.3.6.2 By End User
6.3.3.7 Rest of Europe Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Technology Type
6.3.3.6.2 By End User
6.4 Asia Pacific Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.1 By Technology Type
6.4.2 By End User
6.4.3 By Country
6.4.3.1 China Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.1.1 By Technology Type
6.4.3.1.2 By End User
6.4.3.2 Japan Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.2.1 By Technology Type
6.4.3.2.2 By End User
6.4.3.3 India Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.3.1 By Technology Type
6.4.3.3.2 By End User
6.4.3.4 South Korea Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.4.1 By Technology Type
6.4.3.4.2 By End User
6.4.3.5 Singapore Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.5.1 By Technology Type
6.4.3.5.2 By End User
6.4.3.6 Malaysia Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Technology Type
6.4.3.6.2 By End User
6.4.3.7 Thailand Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Technology Type
6.4.3.6.2 By End User
6.4.3.8 Indonesia Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.7.1 By Technology Type
6.4.3.7.2 By End User
6.4.3.9 Vietnam Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.8.1 By Technology Type
6.4.3.8.2 By End User
6.4.3.10 Taiwan Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.10.1 By Technology Type
6.4.3.10.2 By End User
6.4.3.11 Rest of Asia Pacific Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.11.1 By Technology Type
6.4.3.11.2 By End User
6.5 Middle East and Africa Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.1 By Technology Type
6.5.2 By End User
6.5.3 By Country
6.5.3.1 Saudi Arabia Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.1.1 By Technology Type
6.5.3.1.2 By End User
6.5.3.2 U.A.E. Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.2.1 By Technology Type
6.5.3.2.2 By End User
6.5.3.3 Israel Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.3.1 By Technology Type
6.5.3.3.2 By End User
6.5.3.4 South Africa Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.4.1 By Technology Type
6.5.3.4.2 By End User
6.5.3.5 Rest of Middle East and Africa Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.5.1 By Technology Type
6.5.3.5.2 By End User
6.6 Central & South America Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.1 By Technology Type
6.6.2 By End User
6.6.3 By Country
6.6.3.1 Brazil Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.1.1 By Technology Type
6.6.3.1.2 By End User
6.6.3.2 Argentina Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.2.1 By Technology Type
6.6.3.2.2 By End User
6.6.3.3 Chile Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Technology Type
6.6.3.3.2 By End User
6.6.3.3 Rest of Central & South America Companion Diagnostics Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Technology Type
6.6.3.3.2 By End User
7 COMPETITIVE LANDCAPE
7.1 Company Market Share Analysis
7.2 Four Quadrant Positioning Matrix
7.2.1 Market Leaders
7.2.2 Market Visionaries
7.2.3 Market Challengers
7.2.4 Niche Market Players
7.3 Vendor Landscape
7.3.1 North America
7.3.2 Europe
7.3.3 Asia Pacific
7.3.4 Rest of the World
7.4 Company Profiles
7.4.1 Abbott
7.4.1.1 Business Description & Financial Analysis
7.4.1.2 SWOT Analysis
7.4.1.3 Products & Services Offered
7.4.1.4 Strategic Alliances between Business Partners
7.4.2 F. Hoffmann-La Roche Ltd.
7.4.2.1 Business Description & Financial Analysis
7.4.2.2 SWOT Analysis
7.4.2.3 Products & Services Offered
7.4.2.4 Strategic Alliances between Business Partners
7.4.3 Agilent Technologies Inc.
7.4.3.1 Business Description & Financial Analysis
7.4.3.2 SWOT Analysis
7.4.3.3 Products & Services Offered
7.4.3.4 Strategic Alliances between Business Partners
7.4.4 Illumina Inc.
7.4.4.1 Business Description & Financial Analysis
7.4.4.2 SWOT Analysis
7.4.4.3 Products & Services Offered
7.4.4.4 Strategic Alliances between Business Partners
7.4.5 Guardant Health
7.4.5.1 Business Description & Financial Analysis
7.4.5.2 SWOT Analysis
7.4.5.3 Products & Services Offered
7.4.5.4 Strategic Alliances between Business Partners
7.4.6 Thermo Fisher Scientific
7.4.6.1 Business Description & Financial Analysis
7.4.6.2 SWOT Analysis
7.4.6.3 Products & Services Offered
7.4.6.4 Strategic Alliances between Business Partners
7.4.7 Biomerieux
7.4.7.1 Business Description & Financial Analysis
7.4.7.2 SWOT Analysis
7.4.7.3 Products & Services Offered
7.4.7.4 Strategic Alliances between Business Partners
7.4.8 Qiagen
7.4.8.1 Business Description & Financial Analysis
7.4.8.2 SWOT Analysis
7.4.8.3 Products & Services Offered
7.4.8.4 Strategic Alliances between Business Partners
7.4.9 Myriad Genetics
7.4.9.1 Business Description & Financial Analysis
7.4.9.2 SWOT Analysis
7.4.9.3 Products & Services Offered
7.4.9.4 Strategic Alliances between Business Partners
7.4.10 Medtronic Plc
7.4.10.1 Business Description & Financial Analysis
7.4.10.2 SWOT Analysis
7.4.10.3 Products & Services Offered
7.4.10.4 Strategic Alliances between Business Partners
7.4.11 Other Companies
7.4.11.1 Business Description & Financial Analysis
7.4.11.2 SWOT Analysis
7.4.11.3 Products & Services Offered
7.4.11.4 Strategic Alliances between Business Partners
8 RESEARCH METHODOLOGY
8.1 Market Introduction
8.1.1 Market Definition
8.1.2 Market Scope & Segmentation
8.2 Information Procurement
8.2.1 Secondary Research
8.2.1.1 Purchased Databases
8.2.1.2 GMEs Internal Data Repository
8.2.1.3 Secondary Resources & Third Party Perspectives
8.2.1.4 Company Information Sources
8.2.2 Primary Research
8.2.2.1 Various Types of Respondents for Primary Interviews
8.2.2.2 Number of Interviews Conducted throughout the Research Process
8.2.2.3 Primary Stakeholders
8.2.2.4 Discussion Guide for Primary Participants
8.2.3 Expert Panels
8.2.3.1 Expert Panels Across 30+ Industry
8.2.4 Paid Local Experts
8.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
8.3 Market Estimation
8.3.1 Top-Down Approach
8.3.1.1 Macro-Economic Indicators Considered
8.3.1.2 Micro-Economic Indicators Considered
8.3.2 Bottom Up Approach
8.3.2.1 Company Share Analysis Approach
8.3.2.2 Estimation of Potential Product Sales
8.4 Data Triangulation
8.4.1 Data Collection
8.4.2 Time Series, Cross Sectional & Panel Data Analysis
8.4.3 Cluster Analysis
8.5 Analysis and Output
8.5.1 Inhouse AI Based Real Time Analytics Tool
8.5.2 Output From Desk & Primary Research
8.6 Research Assumptions & Limitations
8.6.1 Research Assumptions
8.6.2 Research Limitations
LIST OF TABLES
1 Global Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
2 Polymerase Chain Reaction Market, By Region, 2021-2029 (USD Million)
3 Next Generation Gene Sequencing Market, By Region, 2021-2029 (USD Million)
4 Immunohistochemistry Market, By Region, 2021-2029 (USD Million)
5 In-situ Hybridization Market, By Region, 2021-2029 (USD Million)
6 Others Market, By Region, 2021-2029 (USD Million)
7 Global Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
8 Pharmaceutical & Biopharmaceutical Companies Market, By Region, 2021-2029 (USD Million)
9 Reference Laboratories Market, By Region, 2021-2029 (USD Million)
10 CROs Market, By Region, 2021-2029 (USD Million)
11 Others Market, By Region, 2021-2029 (USD Million)
12 Regional Analysis, 2021-2029 (USD Million)
13 North America Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
14 North America Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
15 North America Companion Diagnostics Market, By Country, 2021-2029 (USD Million)
16 U.S. Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
17 U.S. Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
18 Canada Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
19 Canada Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
20 Mexico Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
21 Mexico Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
22 Europe Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
23 Europe Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
24 Europe Companion Diagnostics Market, By Country, 2021-2029 (USD Million)
25 Germany Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
26 Germany Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
27 U.K. Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
28 U.K. Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
29 France Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
30 France Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
31 Italy Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
32 Italy Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
33 Spain Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
34 Spain Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
35 Netherlands Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
36 Netherlands Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
37 Rest Of Europe Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
38 Rest Of Europe Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
39 Asia Pacific Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
40 Asia Pacific Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
41 Asia Pacific Companion Diagnostics Market, By Country, 2021-2029 (USD Million)
42 China Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
43 China Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
44 Japan Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
45 Japan Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
46 India Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
47 India Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
48 South Korea Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
49 South Korea Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
50 Singapore Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
51 Singapore Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
52 Thailand Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
53 Thailand Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
54 Malaysia Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
55 Malaysia Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
56 Indonesia Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
57 Indonesia Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
58 Vietnam Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
59 Vietnam Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
60 Taiwan Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
61 Taiwan Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
62 Rest of APAC Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
63 Rest of APAC Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
64 Middle East and Africa Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
65 Middle East and Africa Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
66 Middle East and Africa Companion Diagnostics Market, By Country, 2021-2029 (USD Million)
67 Saudi Arabia Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
68 Saudi Arabia Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
69 UAE Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
70 UAE Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
71 Israel Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
72 Israel Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
73 South Africa Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
74 South Africa Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
75 Rest Of Middle East and Africa Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
76 Rest Of Middle East and Africa Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
77 Central & South America Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
78 Central & South America Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
79 Central & South America Companion Diagnostics Market, By Country, 2021-2029 (USD Million)
80 Brazil Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
81 Brazil Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
82 Chile Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
83 Chile Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
84 Argentina Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
85 Argentina Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
86 Rest Of Central & South America Companion Diagnostics Market, By Technology Type, 2021-2029 (USD Million)
87 Rest Of Central & South America Companion Diagnostics Market, By End User, 2021-2029 (USD Million)
88 Abbott: Products & Services Offering
89 F. Hoffmann-La Roche Ltd.: Products & Services Offering
90 Agilent Technologies Inc.: Products & Services Offering
91 Illumina Inc.: Products & Services Offering
92 Guardant Health: Products & Services Offering
93 Thermo Fisher Scientific: Products & Services Offering
94 Biomerieux : Products & Services Offering
95 Qiagen: Products & Services Offering
96 Myriad Genetics, Inc: Products & Services Offering
97 Medtronic Plc: Products & Services Offering
98 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Companion Diagnostics Market Overview
2 Global Companion Diagnostics Market Value From 2021-2029 (USD Million)
3 Global Companion Diagnostics Market Share, By Technology Type (2023)
4 Global Companion Diagnostics Market Share, By End User (2023)
5 Global Companion Diagnostics Market, By Region (Global Market)
6 Technological Trends In Global Companion Diagnostics Market
7 Four Quadrant Competitor Positioning Matrix
8 Impact Of Macro & Micro Indicators On The Market
9 Impact Of Key Drivers On The Global Companion Diagnostics Market
10 Impact Of Challenges On The Global Companion Diagnostics Market
11 Porter’s Five Forces Analysis
12 Global Companion Diagnostics Market: By Technology Type Scope Key Takeaways
13 Global Companion Diagnostics Market, By Technology Type Segment: Revenue Growth Analysis
14 Polymerase Chain Reaction Market, By Region, 2021-2029 (USD Million)
15 Next Generation Gene Sequencing Market, By Region, 2021-2029 (USD Million)
16 Immunohistochemistry Market, By Region, 2021-2029 (USD Million)
17 In-situ Hybridization Market, By Region, 2021-2029 (USD Million)
18 Others Market, By Region, 2021-2029 (USD Million)
19 Global Companion Diagnostics Market: By End User Scope Key Takeaways
20 Global Companion Diagnostics Market, By End User Segment: Revenue Growth Analysis
21 Pharmaceutical & Biopharmaceutical Companies Market, By Region, 2021-2029 (USD Million)
22 Reference Laboratories Market, By Region, 2021-2029 (USD Million)
23 CROs Market, By Region, 2021-2029 (USD Million)
24 Others Market, By Region, 2021-2029 (USD Million)
25 Regional Segment: Revenue Growth Analysis
26 Global Companion Diagnostics Market: Regional Analysis
27 North America Companion Diagnostics Market Overview
28 North America Companion Diagnostics Market, By Technology Type
29 North America Companion Diagnostics Market, By End User
30 North America Companion Diagnostics Market, By Country
31 U.S. Companion Diagnostics Market, By Technology Type
32 U.S. Companion Diagnostics Market, By End User
33 Canada Companion Diagnostics Market, By Technology Type
34 Canada Companion Diagnostics Market, By End User
35 Mexico Companion Diagnostics Market, By Technology Type
36 Mexico Companion Diagnostics Market, By End User
37 Four Quadrant Positioning Matrix
38 Company Market Share Analysis
39 Abbott: Company Snapshot
40 Abbott: SWOT Analysis
41 Abbott: Geographic Presence
42 F. Hoffmann-La Roche Ltd.: Company Snapshot
43 F. Hoffmann-La Roche Ltd.: SWOT Analysis
44 F. Hoffmann-La Roche Ltd.: Geographic Presence
45 Agilent Technologies Inc.: Company Snapshot
46 Agilent Technologies Inc.: SWOT Analysis
47 Agilent Technologies Inc.: Geographic Presence
48 Illumina Inc.: Company Snapshot
49 Illumina Inc.: Swot Analysis
50 Illumina Inc.: Geographic Presence
51 Guardant Health: Company Snapshot
52 Guardant Health: SWOT Analysis
53 Guardant Health: Geographic Presence
54 Thermo Fisher Scientific: Company Snapshot
55 Thermo Fisher Scientific: SWOT Analysis
56 Thermo Fisher Scientific: Geographic Presence
57 Biomerieux : Company Snapshot
58 Biomerieux : SWOT Analysis
59 Biomerieux : Geographic Presence
60 Qiagen: Company Snapshot
61 Qiagen: SWOT Analysis
62 Qiagen: Geographic Presence
63 Myriad Genetics, Inc.: Company Snapshot
64 Myriad Genetics, Inc.: SWOT Analysis
65 Myriad Genetics, Inc.: Geographic Presence
66 Medtronic Plc: Company Snapshot
67 Medtronic Plc: SWOT Analysis
68 Medtronic Plc: Geographic Presence
69 Other Companies: Company Snapshot
70 Other Companies: SWOT Analysis
71 Other Companies: Geographic Presence
The Global Companion Diagnostics Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Companion Diagnostics Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
